Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?

Life Sciences

Volumn 91, Issue 13-14, 2012, Pages 528-539

  Kohan, Donald E ^a   Cleland, John G ^b   Rubin, Lewis J ^c   Theodorescu, Dan ^d   Barton, Matthias ^e  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adverse event; Clinical trial; Drug dose; Edema; Fluid retention; Metastasis; Myocardial infarction; Patients; Proteinuria; Side effects

Indexed keywords

AMBRISENTAN; ATRASENTAN; AVOSENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; GUANFACINE; MACITENTAN; SITAXSENTAN; ZIBOTENTAN;

ACUTE HEART FAILURE; ALTITUDE DISEASE; ARTERIAL OXYGEN TENSION; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL MEDICINE; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CYSTECTOMY; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; ESSENTIAL HYPERTENSION; FINGER ULCER; FLUID RETENTION; GLOMERULONEPHRITIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIVER FAILURE; LIVER TOXICITY; LYMPHANGIOGENESIS; METASTASIS; NEOPLASM; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROSTATE CANCER; PROSTATE CARCINOMA; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESISTANT HYPERTENSION; SCLERODERMA; SIDE EFFECT; SODIUM RETENTION; STUDY DESIGN; SUBARACHNOID HEMORRHAGE; TERATOGENESIS; TESTIS DISEASE; UNITED KINGDOM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NEOPLASMS; PATIENT SELECTION; RECEPTORS, ENDOTHELIN; STROKE; SUBARACHNOID HEMORRHAGE;

EID: 84867578602     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.07.034     Document Type: Conference Paper

References (198)

1. M.A. Abd-Elsalam Bosentan, a selective and more potent antagonist for Atractaspis envenomation than the specific antivenom Toxicon 57 6 2011 861 870
2. D. Ahn, Y. Ge, P.K. Stricklett, P. Gill, D. Taylor, and A.K. Hughes Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention J Clin Invest 114 4 2004 504 511
3. I. Anand, J. McMurray, J.N. Cohn, M.A. Konstam, T. Notter, and K. Quitzau Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial Lancet 364 9431 2004 347 354
4. D. Andress, B. Coll, Y. Pritchett, J. Brennan, M. Molitch, and D. Kohan Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD) Life Sci 91 13-14 2012 732 735 (this issue)
5. H. Arai, S. Hori, I. Aramori, H. Ohkubo, and S. Nakanishi Cloning and expression of a cDNA encoding an endothelin receptor Nature 348 6303 1990 730 732
6. R.A. Atkinson, and J.T. Pelton Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist FEBS Lett 296 1 1992 1 6
7. A. Bagnato, and L. Rosano The endothelin axis in cancer Int J Biochem Cell Biol 50 2008 1443 1451
8. G.L. Bakris, L.H. Lindholm, H.R. Black, H. Krum, S. Linas, and J.V. Linseman Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial Hypertension 56 5 2010 824 830
9. R.J. Barst, D. Langleben, A. Frost, E.M. Horn, R. Oudiz, and S. Shapiro Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 4 2004 441 447
10. R.J. Barst, D. Langleben, D. Badesch, A. Frost, E.C. Lawrence, and S. Shapiro Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol 47 10 2006 2049 2056
11. M. Barton Reversal of proteinuric renal disease and the emerging role of endothelin Nat Clin Pract Nephrol 4 9 2008 490 501
12. M. Barton Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans Biochim Biophys Acta 1802 12 2010 1203 1213
13. M. Barton, and D.E. Kohan Endothelin antagonists in clinical trials: lessons learned Contrib Nephrol 172 2011 255 260
14. M. Barton, and M. Yanagisawa Endothelin: 20 years from discovery to therapy Can J Physiol Pharmacol 86 8 2008 485 498
15. M. Barton, J.J. Mullins, M.A. Bailey, and M. Kretzler Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials Hypertension 48 5 2006 834 837
16. B. Battistini, N. Berthiaume, N.F. Kelland, D.J. Webb, and D.E. Kohan Profile of past and current clinical trials involving endothelin receptor antagonists: the novel -sentan class of drug Exp Biol Med (Maywood) 231 6 2006 653 695
17. M.K. Bazil, R.W. Lappe, and R.L. Webb Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats J Cardiovasc Pharmacol 20 6 1992 940 948
18. F. Bellisai, G. Morozzi, F. Scaccia, F. Chellini, A. Simpatico, and G. Pecetti Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis Int J Immunopathol Pharmacol 24 1 2011 261 264
19. A. Benigni, D. Corna, R. Maffi, G. Benedetti, C. Zoja, and G. Remuzzi Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy Kidney Int 54 2 1998 353 359
20. A. Benigni, N. Perico, and G. Remuzzi The potential of endothelin antagonism as a therapeutic approach Expert Opin Investig Drugs 13 11 2004 1419 1435
21. G.S. Bleumink, A.M. Knetsch, M.C. Sturkenboom, S.M. Straus, A. Hofman, and J.W. Deckers Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study Eur Heart J 25 18 2004 1614 1619
22. M.H. Bolli, C. Boss, C. Binkert, S. Buchmann, D. Bur, and P. Hess The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4- pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist J Med Chem 2012 Aug 3 [Electronic publication ahead of print]
23. V. Breu, B.M. Loffler, and M. Clozel In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors FEBS Lett 334 2 1993 210 214
24. R.J. Buckanovich, A. Facciabene, S. Kim, F. Benencia, D. Sasaroli, and K. Balint Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy Nat Med 14 1 2008 28 36
25. M. Burnier, and V. Forni Endothelin receptor antagonists: a place in the management of essential hypertension? Nephrol Dial Transplant 27 3 2012 865 868
26. L. Cai, S. Chen, T. Evans, D.X. Deng, K. Mukherjee, and S. Chakrabarti Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism Urol Res 28 5 2000 342 347
27. D. Cella, D.P. Petrylak, M. Fishman, C. Teigland, J. Young, and P. Mulani Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? Eur Urol 49 5 2006 781 789
28. R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, and V.F. Tapson Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 9288 2001 1119 1123
29. J.G. Cleland Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse? Nat Clin Pract Cardiovasc Med 3 5 2006 234 235
30. J.G. Cleland, and A.L. Clark Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth J Am Coll Cardiol 42 7 2003 1234 1237
31. J.G. Cleland, and C.M. Oakley Vascular tone in heart failure: the neuroendocrine-therapeutic interface Br Heart J 66 4 1991 264 267
32. J.G. Cleland, A. Khand, and A. Clark The heart failure epidemic: exactly how big is it? Eur Heart J 22 8 2001 623 626
33. J.G. Cleland, K. Swedberg, F. Follath, M. Komajda, A. Cohen-Solal, and J.C. Aguilar The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis Eur Heart J 24 5 2003 442 463
34. J.G. Cleland, R. Shelton, N. Nikitin, S. Ford, L. Frison, and M. Grind Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials Eur J Heart Fail 9 6-7 2007 730 739
35. J.G. Cleland, J.J. McMurray, J. Kjekshus, J.H. Cornel, P. Dunselman, and C. Fonseca Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) J Am Coll Cardiol 54 20 2009 1850 1859
36. J.G. Cleland, A. Yassin, Y. Arrow, J. Taylor, G. Britchford, and K.M. Goode Outcome of patients discharged on loop diuretic therapy with or without a diagnosis of heart failure Eur J Heart Fail Suppl. 8(2) 2009 1126 [(abstract)]
37. J.G. Cleland, T. McDonagh, A.S. Rigby, A. Yassin, T. Whittaker, and H.J. Dargie The national heart failure audit for England and Wales 2008-2009 Heart 97 11 2011 876 886
38. M. Clozel Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research Sci Transl Med 3 67 2011 67cm2
39. M. Clozel, V. Breu, K. Burri, J.M. Cassal, W. Fischli, and G.A. Gray Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist Nature 365 6448 1993 759 761
40. M. Clozel, V. Breu, G.A. Gray, B. Kalina, B.M. Loffler, and K. Burri Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist J Pharmacol Exp Ther 270 1 1994 228 235
41. R.J. Cody, G.J. Haas, P.F. Binkley, Q. Capers, and R. Kelley Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure Circulation 85 2 1992 504 509
42. A.P. Coletta, and J.G.F. Cleland Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology. WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME Eur J Heart Fail 3 6 2001 747 750
43. A. Coletta, S. Thackray, N. Nikitin, and J.G. Cleland Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL Eur J Heart Fail 4 3 2002 381 388
44. F.S. Collins Mining for therapeutic gold Nat Rev Drug Discov 10 6 2011 397
45. V. Concas, S. Laurent, A.M. Brisac, C. Perret, and M. Safar Endothelin has potent direct inotropic and chronotropic effects in cultured heart cells J Hypertens Suppl 7 6 1989 S96 S97
46. G. Cotter, E. Kaluski, K. Stangl, R. Pacher, C. Richter, and O. Milo-Cotter The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Eur J Heart Fail 6 5 2004 601 609
47. P.J. Cowburn, J.G. Cleland, J.D. McArthur, M.R. MacLean, H.J. Dargie, and J.J. McMurray Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction Cardiovasc Res 39 3 1998 563 570
48. P.J. Cowburn, J.G. Cleland, J.D. McArthur, M.R. MacLean, J.J. McMurray, and H.J. Dargie Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction J Am Coll Cardiol 33 4 1999 932 938
49. P.J. Cowburn, J.G. Cleland, T.A. McDonagh, J.D. McArthur, H.J. Dargie, and J.J. Morton Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure Eur J Heart Fail 7 1 2005 37 42
50. T. Damy, K.M. Goode, A. Kallvikbacka-Bennett, C. Lewinter, J. Hobkirk, and N.P. Nikitin Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure Eur Heart J 31 18 2010 2280 2290
51. T. Damy, A. Kalvikbacka-Bennett, K.M. Goode, and J.G. Cleland Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among outpatients referred for the evaluation of heart failure J Card Fail 18 3 2012 216 225
52. R. de Silva, N.P. Nikitin, K.K. Witte, A.S. Rigby, K. Goode, and S. Bhandari Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis Eur Heart J 27 5 2006 569 581
53. R. de Silva, A.S. Rigby, K.K. Witte, N.P. Nikitin, L. Tin, and K. Goode Anemia, renal dysfunction, and their interaction in patients with chronic heart failure Am J Cardiol 98 3 2006 391 398
54. N. Dhaun, J. Goddard, and D.J. Webb The endothelin system and its antagonism in chronic kidney disease J Am Soc Nephrol 17 4 2006 943 955
55. N. Dhaun, J. Goddard, and D.J. Webb Endothelin antagonism in patients with nondiabetic chronic kidney disease Contrib Nephrol 172 2011 243 254
56. S. Dhillon Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis Drugs 69 14 2009 2005 2024
57. C. Eriksson, A. Gustavsson, T. Kronvall, and C. Tysk Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature J Gastrointestin Liver Dis 20 1 2011 77 80
58. T. Fukuroda, M. Nishikibe, Y. Ohta, M. Ihara, M. Yano, and K. Ishikawa Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153 Life Sci 50 15 1992 PL107 PL112
59. N.B. Gabler, B. French, B.L. Strom, Z. Liu, H.I. Palevsky, and D.B. Taichman Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension Chest 141 1 2012 20 26
60. E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara, and M. Rossi Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol 297 5 2009 F1448 F1456
61. N. Galie, D. Badesch, R. Oudiz, G. Simonneau, M.D. McGoon, and A.M. Keogh Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 3 2005 529 535
62. N. Galie, M. Beghetti, M.A. Gatzoulis, J. Granton, R.M. Berger, and A. Lauer Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 1 2006 48 54
63. N. Galie, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, and H.A. Ghofrani Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 23 2008 3010 3019
64. N. Galie, L. Rubin, M. Hoeper, P. Jansa, H. Al-Hiti, and G. Meyer Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 9630 2008 2093 2100
65. N. Galie, M.M. Hoeper, J. Simon, R. Gibbs, and G. Simonneau For the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Liver toxicity of sitaxentan in pulmonary arterial hypertension Eur Heart J 32 4 2011 386 387
66. C.E. Gariepy, T. Ohuchi, S.C. Williams, J.A. Richardson, and M. Yanagisawa Salt-sensitive hypertension in endothelin-B receptor-deficient rats J Clin Invest 105 7 2000 925 933
67. Y. Ge, D. Ahn, P.K. Stricklett, A.K. Hughes, M. Yanagisawa, and J.G. Verbalis Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality Am J Physiol Renal Physiol 288 5 2005 F912 F920
68. A. Giaid, M. Yanagisawa, D. Langleben, R.P. Michel, R. Levy, and H. Shennib Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 24 1993 1732 1739
69. M.M. Givertz, W.S. Colucci, T.H. LeJemtel, S.S. Gottlieb, J.M. Hare, and M.T. Slawsky Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure Circulation 101 25 2000 2922 2927
70. J. Goddard, C. Eckhart, N.R. Johnston, A.D. Cumming, A.J. Rankin, and D.J. Webb Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism J Am Soc Nephrol 15 10 2004 2601 2610
71. J.M. Good, P. Nihoyannopoulos, M.A. Ghatei, D. Crossman, S.R. Bloom, and P. Clark Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J 15 12 1994 1634 1640
72. Grass W. Sicherheit und Verträglichkeit, Pharmakokinetik, und Pharmacodynamic des selectiven Endothelin A Rezeptor-Antagonistsn SPP301 bei oraler Mehrfachadministration an gesunde, männliche Probanden [thesis]. 2006, Institut für Klinische Pharmakologie, Basel, Switzerland, University of Bonn, Germany. 1-86. 2006.
73. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 6 2010 883 899
74. G. Groenewegen, M. Walraven, J. Vermaat, B. de Gast, E. Witteveen, and R. Giles Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma Br J Cancer 106 2 2012 284 289
75. J.W. Growcott Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054 Anticancer Drugs 20 2 2009 83 88
76. A. Gulati, E.S. Sunila, and G. Kuttan IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's lymphoma ascites tumor model Arzneimittelforschung 62 1 2011 14 17
77. V.P. Harjola, F. Follath, M.S. Nieminen, D. Brutsaert, K. Dickstein, and H. Drexler Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure Eur J Heart Fail 12 3 2011 239 248
78. B. Harrison, M.H. Magee, A. Mandagere, G. Walker, C. Dufton, and L.S. Henderson Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study Clin Drug Investig 30 12 2010 875 885
79. W.G. Haynes, and D.J. Webb Endothelium-dependent modulation of responses to endothelin-I in human veins Clin Sci (Lond) 84 4 1993 427 433
80. M.M. Hoeper Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 34 3 2009 529 530
81. M.M. Hoeper, K.M. Olsson, A. Schneider, and H. Golpon Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy Eur Respir J 33 6 2009 1518 1519
82. Honing MLH, Bouter PK, Ballard DE, Padley P, Morrison PJ, Rabelink TJ. ABT-627, a selective ETA-receptor anatagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-derived Mediators [thesis] 2000;Utrecht, The Netherlands: Elinkwijk BV:89-102.
83. R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, and A. Jadhav The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci Transl Med 3 80 2011 80ps16
84. M. Hulsmann, B. Stanek, B. Frey, B. Sturm, D. Putz, and T. Kos Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure J Am Coll Cardiol 32 6 1998 1695 1700
85. M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, and A. Treiber Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 3 2008 736 745
86. M. Ihara, T. Fukuroda, T. Saeki, M. Nishikibe, K. Kojiri, and H. Suda An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis Biochem Biophys Res Commun 178 1 1991 132 137
87. M. Ihara, K. Noguchi, T. Saeki, T. Fukuroda, S. Tsuchida, and S. Kimura Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor Life Sci 50 4 1992 247 255
88. D. Ivy, I.F. McMurtry, M. Yanagisawa, C.E. Gariepy, T.D. Le Cras, and S.A. Gebb Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction Am J Physiol Lung Cell Mol Physiol 280 5 2001 L1040 L1048
89. X. Jais, A.M. D'Armini, P. Jansa, A. Torbicki, M. Delcroix, and H.A. Ghofrani Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial J Am Coll Cardiol 52 25 2008 2127 2134
90. A. Jimeno, and M. Carducci Atrasentan: a rationally designed targeted therapy for cancer Drugs Today (Barc) 42 5 2006 299 312
91. V. Kalles, G.C. Zografos, X. Provatopoulou, E. Kalogera, P. Liakou, and G. Georgiou Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis Tumour Biol 2012
92. E. Kaluski, I. Kobrin, R. Zimlichman, A. Marmor, O. Krakov, and O. Milo RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 2 2003 204 210
93. L.E. Kandalaft, A. Facciabene, R.J. Buckanovich, and G. Coukos Endothelin B receptor, a new target in cancer immune therapy Clin Cancer Res 15 14 2009 4521 4528
94. N.F. Kelland, and D.J. Webb Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) 231 6 2006 696 699
95. N.F. Kelland, and D.J. Webb Clinical trials of endothelin antagonists in heart failure: publication is good for the public health Heart 93 1 2007 2 4
96. S.J. Kim, J.S. Kim, S.W. Kim, E. Brantley, S.J. Yun, and J. He Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer Neoplasia 13 2 2011 167 179
97. W. Kiowski, G. Sutsch, P. Hunziker, P. Muller, J. Kim, and E. Oechslin Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure Lancet 346 8977 1995 732 736
98. Y.Y. Kisanuki, N. Emoto, T. Ohuchi, B. Widyantoro, K. Yagi, and K. Nakayama Low blood pressure in endothelial cell-specific endothelin 1 knockout mice Hypertension 56 1 2010 121 128
99. Y. Kloog, I. Ambar, M. Sokolovsky, E. Kochva, Z. Wollberg, and A. Bdolah Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain Science 242 4876 1988 268 270
100. D.E. Kohan Endothelin, hypertension and chronic kidney disease: new insights Curr Opin Nephrol Hypertens 19 2010 134 139
101. D.E. Kohan, Y. Pritchett, M. Molitch, S. Wen, T. Garimella, and P. Audhya Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy J Am Soc Nephrol 22 4 2011 763 772
102. D.E. Kohan, N.F. Rossi, E.W. Inscho, and D.M. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol Rev 91 1 2011 1 77
103. 2 online 2011 at http://www.pA2online.org/abstracts/ Vol9Issue1abst015P.pdf
104. I. Komuro, H. Kurihara, T. Sugiyama, M. Yoshizumi, F. Takaku, and Y. Yazaki Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells FEBS Lett 238 2 1988 249 252
105. J.H. Korn, M. Mayes, M. Matucci Cerinic, M. Rainisio, J. Pope, and E. Hachulla Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis Rheum 50 12 2004 3985 3993
106. M.C. Kowala, N. Murugesan, J. Tellew, K. Carlson, H. Monshizadegan, and C. Ryan Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension J Pharmacol Exp Ther 309 1 2004 275 284
107. H. Krum, R.J. Viskoper, Y. Lacourciere, M. Budde, and V. Charlon The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension N Engl J Med 338 1998 784 790
108. A. Kuhn, M. Haust, V. Ruland, R. Weber, P. Verde, and G. Felder Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial Rheumatology (Oxford) 49 7 2010 1336 1345
109. T.W. Kurtz, and U. Klein Next generation multifunctional angiotensin receptor blockers Hypertens Res 32 10 2009 826 834
110. A. Kuryliszyn-Moskal, P.A. Klimiuk, M. Ciolkiewicz, and S. Sierakowski Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus J Rheumatol 35 7 2008 1307 1313
111. M. Lalich, D.G. McNeel, G. Wilding, and G. Liu Endothelin receptor antagonists in cancer therapy Cancer Invest 25 8 2007 785 794
112. R. Lariviere, M. Lebel, I. Kingma, J.H. Grose, and D. Boucher Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass Am J Hypertens 11 8 Pt. 1 1998 989 997
113. T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, and D.G. Souza Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling Am J Transplant 5 5 2005 1042 1049
114. I. Lazich, and G.L. Bakris Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy Contrib Nephrol 172 2011 223 234
115. D.S. Lee, Q.T. Nguyen, N. Lapointe, P.C. Austin, A. Ohlsson, and J.V. Tu Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure J Card Fail 9 5 2003 368 374
116. J.K. Lee, D.M. Havaleshko, H. Cho, J.N. Weinstein, E.P. Kaldjian, and J. Karpovich A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery Proc Natl Acad Sci U S A 104 32 2007 13086 13091
117. D.M. Lloyd-Jones, M.G. Larson, E.P. Leip, A. Beiser, R.B. D'Agostino, and W.B. Kannel Lifetime risk for developing congestive heart failure: the Framingham Heart Study Circulation 106 24 2002 3068 3072
118. A. Louis, J.G. Cleland, S. Crabbe, S. Ford, S. Thackray, and T. Houghton Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001 Eur J Heart Fail 3 3 2001 381 387
119. T.F. Luscher, F. Enseleit, R. Pacher, V. Mitrovic, M.R. Schulze, and R. Willenbrock Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT) Circulation 106 21 2002 2666 2672
120. J.F. Mann, D. Green, K. Jamerson, L.M. Ruilope, S.J. Kuranoff, and T. Littke Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 3 2010 527 535
121. M.D. McGoon, A.E. Frost, R.J. Oudiz, D.B. Badesch, N. Galie, and H. Olschewski Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities Chest 135 1 2009 122 129
122. V.V. McLaughlin, O. Sitbon, D.B. Badesch, R.J. Barst, C. Black, and N. Galie Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2 2005 244 249
123. J.J. McMurray, J.R. Teerlink, G. Cotter, R.C. Bourge, J.G. Cleland, and G. Jondeau Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 17 2007 2009 2019
124. MedPageToday.com FDA lifts liver warning on PAH drug March 5, 2011 http://www.medpagetoday.com/Pulmonology/GeneralPulmonary/25196 (accessed March 19, 2012)
125. P.A. Modesti, I. Cecioni, A. Migliorini, A. Naldoni, A. Costoli, and S. Vanni Increased renal endothelin formation is associated with sodium retention and increased free water clearance Am J Physiol 275 3 Pt. 2 1998 H1070 H1077
126. A. Mohanan, R. Gupta, A. Dubey, V. Jagtap, A. Mandhare, and R.C. Gupta TRC120038, a novel dual AT(1)/ET(A) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 rats Int J Hypertens 2011 2011 751513
127. C.S. Moravec, E.E. Reynolds, R.W. Stewart, and M. Bond Endothelin is a positive inotropic agent in human and rat heart in vitro Biochem Biophys Res Commun 159 1 1989 14 18
128. P. Mulder, V. Richard, G. Derumeaux, M. Hogie, J.P. Henry, and F. Lallemand Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling Circulation 96 6 1997 1976 1982
129. P. Mulder, V. Richard, F. Bouchart, G. Derumeaux, K. Munter, and C. Thuillez Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure Cardiovasc Res 39 3 1998 600 608
130. P. Mulder, H. Boujedaini, V. Richard, G. Derumeaux, J.P. Henry, and S. Renet Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure Circulation 102 5 2000 491 493
131. U. Muller-Ladner, O. Distler, L. Ibba-Manneschi, E. Neumann, and S. Gay Mechanisms of vascular damage in systemic sclerosis Autoimmunity 42 7 2009 587 595
132. N. Murugesan, Z. Gu, L. Fadnis, J.E. Tellew, R.A. Baska, and Y. Yang Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics J Med Chem 48 1 2005 171 179
133. R. Nakov, E. Pfarr, and S. Eberle Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension Am J Hypertens 15 7 Pt 1 2002 583 589
134. J. Nelissen, P. Lemkens, H. Sann, M. Bindl, F. Bassissi, and D. Jasserand Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme Life Sci 91 13-14 2012 586 591 (this issue)
135. J. Nelson, A. Bagnato, B. Battistini, and P. Nisen The endothelin axis: emerging role in cancer Nat Rev Cancer 3 2 2003 110 116
136. J.B. Nelson, W. Love, J.L. Chin, F. Saad, C.C. Schulman, and D.J. Sleep Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 9 2008 2478 2487
137. J.B. Nelson, K. Fizazi, K. Miller, C. Higano, J.W. Moul, and H. Akaza Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 2012 10.1002/cncr.27674 [published online July 11]
138. P.C. Nett, M.M. Teixeira, D. Candinas, and M. Barton Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine Recent Pat Cardiovasc Drug Discov 1 3 2006 265 276
139. W. Neuhofer, and D. Pittrow Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence Eur J Clin Invest 39 Suppl. 2 2009 50 67
140. J.M. Neutel, W.F. Germino, H. Punzi, M. McBride, C.C. Bryson, and R. Belder Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension Circulation 118 2008 [S-886 (abstract)]
141. C.M. O'Connor, W.A. Gattis, K.F. Adams Jr., V. Hasselblad, B. Chandler, and A. Frey Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 9 2003 1452 1457
142. T. Omland, R.T. Lie, A. Aakvaag, T. Aarsland, and K. Dickstein Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction Circulation 89 4 1994 1573 1579
143. H. Ooi, W.S. Colucci, and M.M. Givertz Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan Circulation 106 13 2002 1618 1621
144. S. Orisio, A. Benigni, I. Bruzzi, D. Corna, N. Perico, and C. Zoja Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression Kidney Int 43 2 1993 354 358
145. R. Pacher, B. Stanek, M. Hulsmann, J. Koller-Strametz, R. Berger, and M. Schuller Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure J Am Coll Cardiol 27 3 1996 633 641
146. M. Packer, J. McMurray, B.M. Massie, A. Caspi, V. Charlon, and A. Cohen-Solal Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study J Card Fail 11 1 2005 12 20
147. S.K. Prasad, H.J. Dargie, G.C. Smith, M.M. Barlow, F. Grothues, and B.A. Groenning Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study Heart 92 6 2006 798 803
148. T. Pulido, J. Sandoval, I. Roquet, R. Gutierrez, T. Rueda, and H. Pena Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension Eur J Clin Invest 39 Suppl. 2 2009 14 18
149. B.Z. Qian, and J.W. Pollard Macrophage diversity enhances tumor progression and metastasis Cell 141 1 2010 39 51
150. E. Raichlin, A. Prasad, V. Mathew, B. Kent, D.R. Holmes Jr., and G.M. Pumper Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis Hypertension 52 3 2008 522 528
151. S.G. Raja Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis Curr Opin Investig Drugs 11 9 2010 1066 1073
152. C.E. Raphael, Z.I. Whinnett, J.E. Davies, M. Fontana, E.A. Ferenczi, and C.H. Manisty Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure Heart 95 1 2009 56 62
153. M. Reriani, E. Raichlin, A. Prasad, V. Mathew, G.M. Pumper, and R.E. Nelson Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis Circulation 122 10 2010 958 966
154. Reuters.com Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension http://www.reuters.com/article/2012/04/30/idUS48667+30-Apr-2012+HUG20120430 (accessed July 16, 2012)
155. R.J. Rodeheffer, A. Lerman, D.M. Heublein, and J.C. Burnett Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans Mayo Clin Proc 67 8 1992 719 724
156. L. Rosano, F. Spinella, V. Di Castro, M.R. Nicotra, S. Dedhar, and A.G. de Herreros Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells Cancer Res 65 24 2005 11649 11657
157. L. Rosano, V. Di Castro, F. Spinella, M.R. Nicotra, P.G. Natali, and A. Bagnato ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo Mol Cancer Ther 6 7 2007 2003 2011
158. L. Rosano, R. Cianfrocca, S. Masi, F. Spinella, V. Di Castro, and A. Biroccio Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis Proc Natl Acad Sci U S A 106 8 2009 2806 2811
159. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, and A. Keogh Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 12 2002 896 903
160. A. Russo, G. Bronte, S. Rizzo, D. Fanale, F. Di Gaudio, and N. Gebbia Anti-endothelin drugs in solid tumors Expert Opin Emerg Drugs 15 1 2010 27 40
161. N. Said, S. Smith, M. Sanchez-Carbayo, and D. Theodorescu Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer J Clin Invest 121 1 2011 132 147
162. S. Sakai, T. Miyauchi, M. Kobayashi, I. Yamaguchi, K. Goto, and Y. Sugishita Inhibition of myocardial endothelin pathway improves long-term survival in heart failure Nature 384 6607 1996 353 355
163. T. Sakurai, M. Yanagisawa, Y. Takuwa, H. Miyazaki, S. Kimura, and K. Goto Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor Nature 348 6303 1990 732 735
164. J.M. Sasser, J.C. Sullivan, J.L. Hobbs, T. Yamamoto, D.M. Pollock, and P.K. Carmines Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism J Am Soc Nephrol 18 1 2007 143 154
165. C. Schalcher, G. Cotter, L. Reisin, O. Bertel, I. Kobrin, and T.T. Guyene The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure Am Heart J 142 2 2001 340 349
166. M.P. Schneider, E.I. Boesen, and D.M. Pollock Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease Annu Rev Pharmacol Toxicol 47 2007 731 759
167. A. Seed, R.E. Kuc, J.J. Maguire, C. Hillier, F. Johnston, and H. Essers The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans Life Sci 91 13-14 2012 736 741 (this issue)
168. S. Sen, S. Chen, B. Feng, M. Iglarz, and S. Chakrabarti Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist Life Sci 2012
169. G.G. Serneri, P.A. Modesti, I. Cecioni, D. Biagini, A. Migliorini, and A. Costoli Plasma endothelin and renal endothelin are two distinct systems involved in volume homeostasis Am J Physiol 268 5 Pt. 2 1995 H1829 H1837
170. R.J. Shelton, A.L. Clark, G.C. Kaye, and J.G. Cleland The atrial fibrillation paradox of heart failure Congest Heart Fail 16 1 2010 3 9
171. R.V. Shohet, Y.Y. Kisanuki, X.S. Zhao, Z. Siddiquee, F. Franco, and M. Yanagisawa Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy Proc Natl Acad Sci U S A 101 7 2004 2088 2093
172. O. Sitbon, V. Gressin, R. Speich, P.S. Macdonald, M. Opravil, and D.A. Cooper Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension Am J Respir Crit Care Med 170 11 2004 1212 1217
173. O. Sitbon, V.V. McLaughlin, D.B. Badesch, R.J. Barst, C. Black, and N. Galie Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol Thorax 60 12 2005 1025 1030
174. J. Smolander, B. Vogt, M. Maillard, C. Zweiacker, T. Littke, and T. Hengelage Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects Clin Pharmacol Ther 85 6 2009 628 634
175. M.L. Spangler, and S. Saxena Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli Clin Ther 32 1 2010 53 56
176. M.J. Spinella, A.B. Malik, J. Everitt, and T.T. Andersen Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction Proc Natl Acad Sci U S A 88 16 1991 7443 7446
177. F. Spinella, E. Garrafa, V. Di Castro, L. Rosano, M.R. Nicotra, and A. Caruso Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade Cancer Res 69 6 2009 2669 2676
178. N.R. Srinivas Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors-assembling the clues Br J Clin Pharmacol 67 4 2009 475 477
179. P.S. Steeg, and D. Theodorescu Metastasis: a therapeutic target for cancer Nat Clin Pract Oncol 5 4 2008 206 219
180. D.J. Stewart, R.D. Levy, P. Cernacek, and D. Langleben Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114 6 1991 464 469
181. G. Sutsch, and M. Barton Endothelin in heart failure Curr Hypertens Rep 1 1 1999 62 68
182. G. Sutsch, W. Kiowski, X.W. Yan, P. Hunziker, S. Christen, and W. Strobel Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure Circulation 98 21 1998 2262 2268
183. B. Titus, H.F. Frierson Jr., M. Conaway, K. Ching, T. Guise, and J. Chirgwin Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2 Cancer Res 65 16 2005 7320 7327
184. 2 online 2011 at http://www.pA2online.org/abstracts/Vol9Issue1abst028P.pdf
185. A. Torabi, J.G. Cleland, N.K. Khan, P.H. Loh, A.L. Clark, and F. Alamgir The timing of development and subsequent clinical course of heart failure after a myocardial infarction Eur Heart J 29 7 2008 859 870
186. A. Torabi, A.S. Rigby, and J.G. Cleland Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction J Am Coll Cardiol 55 1 2009 79 81 [author reply]
187. J. Venitz, J. Zack, H. Gillies, M. Allard, J. Regnault, and C. Dufton Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension J Clin Pharmacol 2012 10.1177/0091270011423662
188. D. Vetter, S.G. Shaw, R.P. Brandes, K. Munter, W. Vetter, and M. Barton Beneficial cardiovascular effects of endothelin ET(A) receptor blockade in established long-term heart failure after myocardial infarction Exp Biol Med (Maywood) 231 6 2006 857 860
189. G. Walker, A. Mandagere, C. Dufton, and J. Venitz The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers Br J Clin Pharmacol 67 5 2009 527 534
190. T. Watanabe, K. Kusumoto, T. Kitayoshi, and N. Shimamoto Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of L-type calcium channels J Cardiovasc Pharmacol 13 Suppl. 5 1989 S108 S111 [discussion s23]
191. D.J. Webb DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension Hypertension 56 5 2010 806 807
192. M.A. Weber, H. Black, G. Bakris, H. Krum, S. Linas, and R. Weiss A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial Lancet 374 9699 2009 1423 1431
193. R.R. Wenzel, T. Littke, S. Kuranoff, C. Jurgens, H. Bruck, and E. Ritz Avosentan reduces albumin excretion in diabetics with macroalbuminuria J Am Soc Nephrol 20 3 2009 655 664
194. B. Widyantoro, N. Emoto, K. Nakayama, D.W. Anggrahini, S. Adiarto, and N. Iwasa Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition Circulation 121 22 2010 2407 2418
195. X.F. Xu, F. Cheng, and L.Z. Du Epigenetic regulation of pulmonary arterial hypertension Hypertens Res 34 9 2011 981 986
196. L.L. Yang, R. Gros, M.G. Kabir, A. Sadi, A.I. Gotlieb, and M. Husain Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice Circulation 109 2 2004 255 261
197. M. Yoshibayashi, K. Nishioka, K. Nakao, Y. Saito, M. Matsumura, and T. Ueda Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation Circulation 84 6 1991 2280 2285
198. X.S. Zhao, W. Pan, R. Bekeredjian, and R.V. Shohet Endogenous endothelin-1 is required for cardiomyocyte survival in vivo Circulation 114 8 2006 830 837